Literature DB >> 20668478

Targeted therapies: Biomarkers in NSCLC for selecting cetuximab therapy.

Thomas E Stinchcombe, Mark A Socinski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20668478     DOI： 10.1038/nrclinonc.2010.99

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  7 in total

1.  Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

Authors:  Alice T Shaw; Beow Y Yeap; Mari Mino-Kenudson; Subba R Digumarthy; Daniel B Costa; Rebecca S Heist; Benjamin Solomon; Hannah Stubbs; Sonal Admane; Ultan McDermott; Jeffrey Settleman; Susumu Kobayashi; Eugene J Mark; Scott J Rodig; Lucian R Chirieac; Eunice L Kwak; Thomas J Lynch; A John Iafrate
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

2.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

3.  Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.

Authors:  Fred R Hirsch; Roy S Herbst; Christine Olsen; Kari Chansky; John Crowley; Karen Kelly; Wilbur A Franklin; Paul A Bunn; Marileila Varella-Garcia; David R Gandara
Journal:  J Clin Oncol       Date:  2008-07-10       Impact factor: 44.544

4.  Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

Authors:  Robert Pirker; Jose R Pereira; Aleksandra Szczesna; Joachim von Pawel; Maciej Krzakowski; Rodryg Ramlau; Ihor Vynnychenko; Keunchil Park; Chih-Teng Yu; Valentyn Ganul; Jae-Kyung Roh; Emilio Bajetta; Kenneth O'Byrne; Filippo de Marinis; Wilfried Eberhardt; Thomas Goddemeier; Michael Emig; Ulrich Gatzemeier
Journal:  Lancet       Date:  2009-05-02       Impact factor: 79.321

5.  Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.

Authors:  Shirin Khambata-Ford; Christopher T Harbison; Lowell L Hart; Melissa Awad; Li-An Xu; Christine E Horak; Shaker Dakhil; Robert C Hermann; Thomas J Lynch; Martin R Weber
Journal:  J Clin Oncol       Date:  2010-01-25       Impact factor: 44.544

6.  Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

Authors:  Thomas J Lynch; Taral Patel; Luke Dreisbach; Michael McCleod; William J Heim; Robert C Hermann; Eugene Paschold; Nicholas O Iannotti; Shaker Dakhil; Steven Gorton; Virginie Pautret; Martin R Weber; Donald Woytowitz
Journal:  J Clin Oncol       Date:  2010-01-25       Impact factor: 44.544

Review 7.  American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.

Authors:  Carmen J Allegra; J Milburn Jessup; Mark R Somerfield; Stanley R Hamilton; Elizabeth H Hammond; Daniel F Hayes; Pamela K McAllister; Roscoe F Morton; Richard L Schilsky
Journal:  J Clin Oncol       Date:  2009-02-02       Impact factor: 44.544
  7 in total
  2 in total

1.  Photoimmunotherapy: comparative effectiveness of two monoclonal antibodies targeting the epidermal growth factor receptor.

Authors:  Kazuhide Sato; Rira Watanabe; Hirofumi Hanaoka; Toshiko Harada; Takahito Nakajima; Insook Kim; Chang H Paik; Peter L Choyke; Hisataka Kobayashi
Journal:  Mol Oncol       Date:  2014-01-22       Impact factor: 6.603

2.  Prognostic value of LIPC in non-small cell lung carcinoma.

Authors:  Lorenzo Galluzzi; Aicha Goubar; Ken André Olaussen; Ilio Vitale; Laura Senovilla; Judith Michels; Angélique Robin; Nicolas Dorvault; Benjamin Besse; Pierre Validire; Pierre Fouret; Carmen Behrens; Ignacio Ivan Wistuba; Jean-Charles Soria; Guido Kroemer
Journal:  Cell Cycle       Date:  2013-01-23       Impact factor: 4.534
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.